Skip to main content
SpringerLink
Log in

Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–6.

    Article  PubMed  Google Scholar 

  3. Towse A, Garrison LP. Can’t get no satisfaction? Will pay for performance help? Pharmacoeconomics. 2010;28:93–102.

    Article  PubMed  Google Scholar 

  4. Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, Drago F. Do the current performance-based schemes in Italy really work? “Success Fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2014. (Epub ahead of print).

  5. van de Vooren K, Curto A, Freemantle N, Garattini L. Market-access agreements for anti-cancer drugs. J R Soc Med. 2015;108(5):166–70.

    Article  PubMed  Google Scholar 

  6. http://www.agenziafarmaco.gov.it/it/content/lista-aggiornata-dei-registri-e-dei-piani-terapeutici-web-based.

  7. AIFA. L’uso dei farmaci in Italia. Rapporto nazionale anno 2014. Osservatorio Nazionale sull’impiego dei Medicinali, OsMed. Roma, 2015. AIFA.

  8. Parkinson B, Elshaug A. Authors’ reply to Palozzo and Messori: ‘‘Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review’’. Pharmacoeconomics. 2016;34(4):421–42.

    Article  PubMed  Google Scholar 

  9. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.

    Article  PubMed  Google Scholar 

  10. Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at italian medicines agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210–3.

    Article  PubMed  Google Scholar 

  11. Scherer FM. The pharmaceutical industry. Prices and progress. N Engl J Med. 2004;351:927–32.

    Article  CAS  PubMed  Google Scholar 

  12. Garattini L, Padula A. ‘Appropriateness’ in Italy: a ‘Magic Word’ in pharmaceuticals? Appl Health Econ Health Policy. 2016 (Epub ahead of print).

Download references

Author information

Authors and Affiliations

  1. CESAV, Centre for Health Economics, IRCCS Institute for Pharmacological Research ‘Mario Negri’, Via Camozzi, 3 c/o Villa Camozzi, Ranica, 24020, Bergamo, Italy

    Livio Garattini & Alessandro Curto

Authors
  1. Livio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Curto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Livio Garattini.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garattini, L., Curto, A. Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?. PharmacoEconomics 34, 967–969 (2016). https://doi.org/10.1007/s40273-016-0420-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-016-0420-1

Keywords

Search

Navigation